A study recently conducted by US Oncology and Aetna found that evidence-based care for patients with non-small cell lung cancer (NSCLC) resulted in an average cost savings of 35% over 12 months while demonstrating equivalent health outcomes.
A study recently conducted by US Oncology and Aetna found that evidence-based care for patients with non-small cell lung cancer (NSCLC) resulted in an average cost savings of 35% over 12 months while demonstrating equivalent health outcomes. This cost difference was driven predominately by lower costs for chemotherapy and other medications. The study, which compared patients treated with evidence-based guidelines (also known as 'on pathway') to those treated with non-evidence-based guidelines (also known as 'off pathway'), was published in the peer-reviewed Journal of Oncology Practice.
The evidence-based medicine pathways are treatment guidelines set by US Oncology's network of physicians based on evidence that has been published in peer-reviewed journals. According to US Oncology, they demonstrate treatment methods that have the best outcomes with the least harmful side effects for the majority of patients. Aetna provided data on the average payer costs for treating NSCLC patients, providing a point of comparison to determine cost savings.
“The Aetna strategy is to recognize physicians who give high quality care - defined as using pathways that speak to the best outcome for the patient and treatments that do not do more harm than good,” says Kirsten Anderson, medical director and Chief of Staff to the Chief Medical Officer at Aetna. “US Oncology’s Pathways reflect our values.”
There is limited empirical evidence regarding the cost-effectiveness of newer treatment strategies. The US Oncology and Aetna study was conducted from July 1, 2006 through Dec. 31, 2007. All NSCLC patients initiating a chemotherapy regimen at eight practices within the US Oncology Network were identified. Of a total 1,409 NSCLC patients, 1,095 (78%) were treated on pathway while 314 (22%) were treated off pathway. The cost data was provided by Aetna and the analysis was conducted from a payer's perspective and considered only direct costs. The study found no observed differences in 12-month overall survival by pathway status.
"To our knowledge, this is the first study to empirically measure the cost-effectiveness of evidence-based treatment guidelines for cancer therapy," says Roy Beveridge, M.D., medical director with US Oncology and investigator on the study. "The results suggest that treating patients according to evidence-based guidelines is a cost-effective strategy for delivering care to patients with NSCLC, especially in the adjuvant and first-line settings. We also found that there were no observed differences in outcomes, suggesting that the added cost associated with treating patients off Pathways did not translate to improved outcomes. This is a great example of cancer care that can save patients, and the nation’s health care system, millions of dollars and produce equally effective results."
Personal Health Information was Released in Change Healthcare Hack
April 23rd 2024UnitedHealth has found 22 screenshots, allegedly from Change Healthcare files, that were posted for about a week on the dark web. Some of these contained personal health information. The extent of data release is not yet known.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Drug Discount Programs Poised to Change with New Tech, Pharma Execs Survey Finds
April 22nd 2024It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue
Read More
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
April 22nd 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More